ReviewCancer cell international2025
Assessing the prognostic value of long non-coding RNAs in glioblastoma patients: findings from a systematic review and meta-analysis.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of peripheral blood fibrinogen-to-albumin ratio in pancreatic cancer patients: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Identification of a lncRNA prognostic signature reveals that SNAI3-AS1 cooperates with erastin to reshape macrophage polarization in glioma.Medical oncology (Northwood, London, England) · 2026Article
- Prognostic value of inflammation-immunity-nutrition score in patients with cancers.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioblastoma multiforme (GBM) is an exceedingly aggressive tumor subtype, comprising 60% of high-grade gliomas and 54% of all gliomas. GBM has poor survival rates despite current treatments, with less than 5% of patients surviving beyond five years. Long Non-coding RNAs (LncRNAs) are essential in gene regulation and tumor advancement. The dysregulation of lncRNAs in GBM suggests their potential as prognostic biomarkers and therapeutic targets, providing insights for personalized treatment strategies. This study aims to evaluate the prognostic significance of lncRNA expression in GBM to enhance the understanding of the disease and inform therapeutic strategies.
methodThis study complied with PRISMA principles, with the protocol registered in PROSPERO. A comprehensive search across PubMed, Scopus, Web of Science, and Embase (2000-2023) identified cohort studies on lncRNA dysregulation and GBM prognosis. Two independent researchers screened and extracted relevant data, resolving discrepancies through a third reviewer. The QUIPS tool assessed bias risk, and statistical analysis employed a random-effects model. Sensitivity analysis, assessment of publication bias (Begg's test, funnel plots), and subgroup analyses were performed to investigate heterogeneity. The reliability of the evidence was evaluated using the modified GRADE technique.
resultThis meta-analysis assessed five lncRNAs with prognostic relevance in GBM patients, revealing that their dysregulated expression correlated with reduced overall survival (HR: 1.37). Dysregulation of MALAT1 had the strongest association with reduced OS (HR: 2.50). Other lncRNAs showed significant associations as follows: HOTAIR (HR: 1.26), NEAT1 (HR: 1.28), H19 (HR: 1.42), and HOTAIRM1 (HR: 1.29). Subgroup analysis indicated stronger prognostic value in low-bias studies (HR: 1.51) and hospital-derived data (HR: 2.51).
conclusionOur study examined the expression of five lncRNAs and identified their potential as prognostic markers for GBM patients. However, evaluating the prognostic value of additional lncRNAs and integrating these into prognostic models alongside other significant GBM biomarkers is recommended for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.